Rakuten Investment Management Inc. Acquires 28,065 Shares of AbbVie Inc. $ABBV

Rakuten Investment Management Inc. boosted its holdings in AbbVie Inc. (NYSE:ABBV) by 9.7% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 317,156 shares of the company’s stock after purchasing an additional 28,065 shares during the period. Rakuten Investment Management Inc.’s holdings in AbbVie were worth $83,504,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the business. Burk Holdings LLC bought a new stake in shares of AbbVie during the 2nd quarter worth $30,000. Marquette Asset Management LLC grew its position in AbbVie by 52.2% during the second quarter. Marquette Asset Management LLC now owns 140 shares of the company’s stock valued at $35,000 after buying an additional 48 shares during the period. IMG Wealth Management Inc. grew its position in AbbVie by 3,060.0% during the second quarter. IMG Wealth Management Inc. now owns 158 shares of the company’s stock valued at $40,000 after buying an additional 153 shares during the period. Principia Wealth Advisory LLC increased its holdings in AbbVie by 38.9% during the second quarter. Principia Wealth Advisory LLC now owns 157 shares of the company’s stock worth $40,000 after buying an additional 44 shares during the last quarter. Finally, Tacita Capital Inc purchased a new stake in AbbVie during the second quarter worth about $42,000. Institutional investors own 70.23% of the company’s stock.

Insider Activity at AbbVie

In related news, EVP Nicholas Donoghoe sold 32,710 shares of the firm’s stock in a transaction that occurred on Friday, August 14th. The shares were sold at an average price of $250.00, for a total value of $8,177,500.00. Following the completion of the transaction, the executive vice president directly owned 74,430 shares of the company’s stock, valued at approximately $18,607,500. This trade represents a 30.53% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.06% of the company’s stock.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie raised its 2026 outlook, projecting EPS of $13.95–$13.99 and revenue of $67.8 billion, both slightly above consensus at the midpoint. Its latest quarter also beat analyst estimates, with revenue up 10.3% year over year. Q3 earnings outlook and pipeline progress
• Positive Sentiment: AbbVie expanded its Oxford R&D facility as part of an investment exceeding £120 million, signaling continued commitment to research and development. Reuters: Oxford R&D expansion
• Positive Sentiment: The company expanded its migraine-drug partnership with Brise in a deal potentially worth up to $757 million, adding to its pipeline prospects. AbbVie-Brise license deal
• Positive Sentiment: Several analysts raised their price targets after the quarterly results, reflecting confidence in AbbVie’s growth transition. Analyst target increases
• Negative Sentiment: Fourth-quarter EPS guidance of $3.83–$3.87 is below the $3.89 consensus, despite revenue guidance of $18.4 billion topping expectations. That earnings shortfall could temper the otherwise stronger full-year outlook.
• Negative Sentiment: After a strong run, valuation concerns remain: one recent analysis described the shares as stretched and questioned how much further growth from Skyrizi and pipeline deals is already reflected in the price. Valuation and upside analysis

AbbVie Stock Performance

Shares of ABBV opened at $285.88 on Wednesday. AbbVie Inc. has a fifty-two week low of $190.75 and a fifty-two week high of $298.74. The business has a 50-day moving average of $270.23 and a 200 day moving average of $237.89. The firm has a market cap of $505.09 billion, a P/E ratio of 49.20, a price-to-earnings-growth ratio of 1.31 and a beta of 0.20.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Friday, October 30th. The company reported $3.82 EPS for the quarter, beating the consensus estimate of $3.73 by $0.09. The business had revenue of $17.40 billion for the quarter, compared to the consensus estimate of $17.32 billion. AbbVie had a net margin of 15.67% and a negative return on equity of 435.41%. The company’s revenue was up 10.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.86 earnings per share. As a group, research analysts predict that AbbVie Inc. will post 14.00 earnings per share for the current fiscal year.

AbbVie Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, February 16th. Stockholders of record on Friday, January 15th will be given a $1.82 dividend. This represents a $7.28 annualized dividend and a dividend yield of 2.5%. This is an increase from AbbVie’s previous quarterly dividend of $1.73. The ex-dividend date of this dividend is Friday, January 15th. AbbVie’s payout ratio is presently 119.10%.

Analyst Ratings Changes

Several brokerages have commented on ABBV. Wolfe Research raised shares of AbbVie from a “peer perform” rating to an “outperform” rating and lifted their price objective for the stock from $235.00 to $300.00 in a research report on Thursday, August 13th. The Goldman Sachs Group increased their target price on shares of AbbVie from $258.00 to $294.00 and gave the company a “neutral” rating in a research report on Friday, October 23rd. Piper Sandler raised their price target on shares of AbbVie from $298.00 to $303.00 and gave the stock an “overweight” rating in a research note on Thursday, August 20th. Morgan Stanley lifted their price target on shares of AbbVie from $310.00 to $346.00 and gave the stock an “overweight” rating in a report on Monday. Finally, Cantor Fitzgerald upped their price objective on AbbVie from $290.00 to $325.00 and gave the company an “overweight” rating in a research note on Monday. One analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and six have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $296.88.

AbbVie Company Profile

AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company’s key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.